About Altasciences
Up Close and Personal with Francis Douville
Francis Douville joined the Altasciences team in 2018, as Senior Vice President, Technical Operations, for our preclinical services.
2019 Year in Review
|
|
2019 was an exceptionally exciting year at Altasciences, and we appreciate you being on the journey with us. We launched our new brand concept to rave reviews, made important additions to our leadership teams, to deliver an integrated discovery to proof of concept service offering. We are confident that 2020 will bring even more exciting times – moving in unison towards a common goal of bringing new drugs to market, faster. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Up Close and Personal with David Grégoire
David Grégoire joined Altasciences as Director of Quality Assurance in 2012.
Up Close and Personal with Mike Broadhurst
Mike Broadhurst joined the Altasciences’ team in 2018.
Brand Identity – Altasciences’ Evolution
Developing a brand identity that fully expresses your company’s contributions is a process that involves understanding your position in the marketplace, establishing your unique selling proposition and associated messaging, developing memorable and impactful creative elements, and finally, implementing strategies to support your brand identity.
Letter From Altasciences' CEO
February 12, 2019
Exceptional service — Lately, it has become an overused expression in our industry. About a year ago, Altasciences set out to explore what exceptional service really means to the people who matter — our clients. After extensive discussions, client surveys, and evaluations, we were pleased to confirm that our early drug development solution offering enables us to provide what our clients want. We also discovered that our brand identity did not accurately communicate our combined early stage drug development capabilities and expertise.
Up Close and Personal with Ingrid Holmes
Ingrid joined Altasciences in 2011, as Vice President of Clinical Operations at the Montreal site, a facility currently housing seven clinical units with 265 beds, and dedicated